123 related articles for article (PubMed ID: 36621146)
21. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S
Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757
[TBL] [Abstract][Full Text] [Related]
22. Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn's Disease.
Ling J; Buurman D; Ravikumara M; Mews C; Thacker K; Grover Z
Dig Dis Sci; 2018 Apr; 63(4):1003-1010. PubMed ID: 29480415
[TBL] [Abstract][Full Text] [Related]
23. Early serum infliximab trough level and mucosal healing could be predictors for one-year outcome after initiating therapy in Crohn's disease.
Tang J; Yang Q; Huang Z; Guo H; Chao K; Hu P; Gao X
Scand J Gastroenterol; 2020 Sep; 55(9):1035-1040. PubMed ID: 32819192
[TBL] [Abstract][Full Text] [Related]
24. Investigation of IL23R, JAK2, and STAT3 gene polymorphisms and gene-gene interactions in Crohn's disease and ulcerative colitis in a Turkish population.
Can G; Tezel A; Gürkan H; Tozkır H; Ünsal G; Soylu AR; Ümit HC
Turk J Gastroenterol; 2016 Nov; 27(6):525-536. PubMed ID: 27852544
[TBL] [Abstract][Full Text] [Related]
25. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.
Hendler SA; Cohen BL; Colombel JF; Sands BE; Mayer L; Agarwal S
J Crohns Colitis; 2015 Mar; 9(3):266-75. PubMed ID: 25540149
[TBL] [Abstract][Full Text] [Related]
26. NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine.
Kim ES; Choi S; Choi SY; Park JH; Choe BH; Lee SY; Kim MJ; Choe YH; Kang B
Aliment Pharmacol Ther; 2022 Apr; 55(8):1008-1015. PubMed ID: 35032047
[TBL] [Abstract][Full Text] [Related]
27. Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease.
Cheng J; Hamilton Z; Smyth M; Barker C; Israel D; Jacobson K
Inflamm Bowel Dis; 2017 Oct; 23(10):1762-1773. PubMed ID: 28837517
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.
Netz U; Carter JV; Eichenberger MR; Dryden GW; Pan J; Rai SN; Galandiuk S
World J Gastroenterol; 2017 Jul; 23(27):4958-4967. PubMed ID: 28785150
[TBL] [Abstract][Full Text] [Related]
29. [Association between drug trough concentration and disease outcome before infliximab maintenance treatment in children with Crohn's disease].
Deng X; Yu Y; Wang XQ; Li J; Xu X; Xu CD; Xiao Y
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Nov; 24(11):1246-1251. PubMed ID: 36398551
[TBL] [Abstract][Full Text] [Related]
30. Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab.
Guerbau L; Gerard R; Duveau N; Staumont-Sallé D; Branche J; Maunoury V; Cattan S; Wils P; Boualit M; Libier L; Cotteau-Leroy A; Desreumaux P; Nachury M; Pariente B
Inflamm Bowel Dis; 2017 Oct; 23(10):1853-1859. PubMed ID: 28837519
[TBL] [Abstract][Full Text] [Related]
31. Evaluating the impact of infliximab use on surgical outcomes in pediatric Crohn's disease.
Abbas PI; Peterson ML; Fallon SC; Lopez ME; Wesson DE; Walsh SM; Kellermayer R; Rodriguez JR
J Pediatr Surg; 2016 May; 51(5):786-9. PubMed ID: 26944181
[TBL] [Abstract][Full Text] [Related]
32. The role of ABO blood groups in Crohn's disease and in monitoring response to infliximab treatment.
Yu Q; Wang L; Zhang S; Feng T; Li L; Chen B; Chen M
Blood Transfus; 2016 Sep; 14(5):460-4. PubMed ID: 27136434
[TBL] [Abstract][Full Text] [Related]
33. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab.
Medrano LM; Taxonera C; Márquez A; Barreiro-de Acosta M; Gómez-García M; González-Artacho C; Pérez-Calle JL; Bermejo F; Lopez-Sanromán A; Martín Arranz MD; Gisbert JP; Mendoza JL; Martín J; Urcelay E; Núñez C
Hum Immunol; 2014 Jan; 75(1):71-5. PubMed ID: 24121042
[TBL] [Abstract][Full Text] [Related]
34. Smoking behaviour modifies IL23r-associated disease risk in patients with Crohn's disease.
Doecke JD; Simms LA; Zhao ZZ; Roberts RL; Fowler EV; Croft A; Lin A; Huang N; Whiteman DC; Florin TH; Barclay ML; Merriman TR; Gearry RB; Montgomery GW; Radford-Smith GL
J Gastroenterol Hepatol; 2015 Feb; 30(2):299-307. PubMed ID: 24989722
[TBL] [Abstract][Full Text] [Related]
35. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.
Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Inflamm Bowel Dis; 2009 Sep; 15(9):1295-301. PubMed ID: 19340881
[TBL] [Abstract][Full Text] [Related]
36. Infliximab Treatment Persistence among Japanese Patients with Chronic Inflammatory Diseases: A Retrospective Japanese Claims Data Study.
Masui S; Yonezawa A; Momo K; Nakagawa S; Itohara K; Imai S; Nakagawa T; Matsubara K
Biol Pharm Bull; 2022; 45(3):323-332. PubMed ID: 35228398
[TBL] [Abstract][Full Text] [Related]
37. B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment.
Andreou NP; Legaki E; Dovrolis N; Boyanov N; Georgiou K; Gkouskou K; Gazouli M
Dig Liver Dis; 2021 May; 53(5):574-580. PubMed ID: 33339749
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study.
Crombé V; Salleron J; Savoye G; Dupas JL; Vernier-Massouille G; Lerebours E; Cortot A; Merle V; Vasseur F; Turck D; Gower-Rousseau C; Lémann M; Colombel JF; Duhamel A
Inflamm Bowel Dis; 2011 Oct; 17(10):2144-52. PubMed ID: 21287665
[TBL] [Abstract][Full Text] [Related]
39. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
Jongsma MME; Aardoom MA; Cozijnsen MA; van Pieterson M; de Meij T; Groeneweg M; Norbruis OF; Wolters VM; van Wering HM; Hojsak I; Kolho KL; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg-Roord STA; Schreurs MWJ; Rizopoulos D; Doukas M; Escher JC; Samsom JN; de Ridder L
Gut; 2022 Jan; 71(1):34-42. PubMed ID: 33384335
[TBL] [Abstract][Full Text] [Related]
40. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
